Coronavirus vaccine development: from SARS and MERS to COVID-19
- PMID: 33341119
- PMCID: PMC7749790
- DOI: 10.1186/s12929-020-00695-2
Coronavirus vaccine development: from SARS and MERS to COVID-19
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development.
Keywords: Coronaviruses; SARS-CoV-2; Vaccine; Vaccine development.
Conflict of interest statement
Dr T.C. Wu is a co-founder of and has an equity ownership interest in Papivax LLC. Additionally Dr. Wu owns Papivax Biotech Inc. stock options and is a member of Papivax Biotech Inc.’s Scientific Advisory Board. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.
Figures


Similar articles
-
Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.Biomed Res Int. 2021 Jan 22;2021:8870425. doi: 10.1155/2021/8870425. eCollection 2021. Biomed Res Int. 2021. PMID: 33564683 Free PMC article. Review.
-
Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.Transbound Emerg Dis. 2021 May;68(3):1111-1124. doi: 10.1111/tbed.13804. Epub 2020 Sep 23. Transbound Emerg Dis. 2021. PMID: 32815655 Free PMC article. Review.
-
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115. Sheng Wu Gong Cheng Xue Bao. 2020. PMID: 32347053 Review. Chinese.
-
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28. Cell. 2020. PMID: 32645327 Free PMC article.
-
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.FEBS J. 2020 Sep;287(17):3633-3650. doi: 10.1111/febs.15375. Epub 2020 Jun 16. FEBS J. 2020. PMID: 32446285 Free PMC article. Review.
Cited by
-
Genome sequencing of SARS-Co-V-2 reveals mutations including F559I and V781D in S protein and LI123-124L in the nsp6 in 21K and 21L clades.Virusdisease. 2024 Sep;35(3):400-419. doi: 10.1007/s13337-024-00876-9. Epub 2024 Jul 8. Virusdisease. 2024. PMID: 39464730
-
Virus-like particles (VLPs): A promising platform for combating against Newcastle disease virus.Vaccine X. 2024 Jan 14;16:100440. doi: 10.1016/j.jvacx.2024.100440. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38283623 Free PMC article. Review.
-
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.J Biomed Sci. 2022 Oct 15;29(1):82. doi: 10.1186/s12929-022-00853-8. J Biomed Sci. 2022. PMID: 36243868 Free PMC article. Review.
-
Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment.Clin Nutr Open Sci. 2022 Apr;42:62-72. doi: 10.1016/j.nutos.2021.12.004. Epub 2022 Jan 28. Clin Nutr Open Sci. 2022. PMID: 35106518 Free PMC article. Review.
-
DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice.Front Immunol. 2022 Feb 24;13:827605. doi: 10.3389/fimmu.2022.827605. eCollection 2022. Front Immunol. 2022. PMID: 35281016 Free PMC article.
References
-
- Centers-for-Disease-Control-and-Prevention. Human Coronavirus Types. 2020. https://www.cdc.gov/coronavirus/types.html.
-
- van der Hoek L. Human coronaviruses: what do they cause? Antivir Ther. 2007;12(4 Pt B):651–658. - PubMed
-
- World-Health-Organization . Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Geneva: World-Health-Organization; 2003.
-
- World-Health-Organization . MERS situation update, January 2020. Geneva: World-Health-Organization; 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous